Atara Biotherapeutics, Inc. Stock Analysis & AI Score
Atara Biotherapeutics, Inc. (ATRA) has an ST Score of 47.2 (C+), driven by its Forecast (A-) and held back by its Profitability (C-). Analysts rate it Hold with a $13.00 price target (+52.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Atara Biotherapeutics, Inc. (ATRA) has an ST Score of 47.2 (C+), driven by its Forecast (A-) and held back by its Profitability (C-). Analysts rate it Hold with a $13.00 price target (+52.2% upside).
- Strongest
- ForecastA-
- Weakest
- ProfitabilityC-
All factor grades
- ForecastA-
- GrowthB
- ValuationC+
- MomentumC+
- Financial StrengthC
- ProfitabilityC-
- Piotroski1/9
Contact
ATRA stock: frequently asked questions
What is ATRA's ST Score?
Atara Biotherapeutics, Inc. (ATRA) has an ST Score of 47.2 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ATRA a buy, hold, or sell?
Analysts rate ATRA a Hold, with a price target of $13.00 (+52.2% vs the current price). Our ST Score grades it C+ (47.2/100). The ST Score is a data-driven signal, not a recommendation.
What are ATRA's factor grades?
Valuation C+, Profitability C-, Financial Strength C, Momentum C+, Growth B, Forecast A-.
What is ATRA's valuation grade?
Atara Biotherapeutics, Inc. (ATRA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ATRA's growth grade?
Atara Biotherapeutics, Inc. (ATRA) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ATRA's profitability grade?
Atara Biotherapeutics, Inc. (ATRA) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ATRA's financial strength grade?
Atara Biotherapeutics, Inc. (ATRA) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ATRA?
The average analyst price target for Atara Biotherapeutics, Inc. (ATRA) is $13.00 from 13 analysts, which is +52.2% versus the recent price of $8.54.
What is ATRA's Piotroski score?
Atara Biotherapeutics, Inc. (ATRA) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.